Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coumarins link iron deficiency to TOR inhibition in plants.

Current biology : CB·2026
Same author

RE: Deployment to Karshi-Khanabad Air Base, Uzbekistan between 2001 and 2005 and subsequent risk of specific cancers among US service members.

Journal of the National Cancer Institute·2026
Same author

Cisplatin resistance in an ovarian cancer model is mediated by microtubule dynamics regulator TPPP3 in synergy with tubulin code rewiring.

Cell reports·2026
Same author

A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells.

Molecular cancer therapeutics·2026
Same author

Functional implications of the conformational landscape of a multidrug transporter revealed by Zebrafish Abcb4 structures.

Nature communications·2026
Same author

Clarifying transfusion-associated graft-versus-host disease risk in modern Hodgkin lymphoma survivorship.

Transfusion·2026

Related Experiment Video

Updated: Dec 23, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K

The Evolving AML Genomic Landscape: Therapeutic Implications.

Sachi Horibata1, George Alyateem1, Christin B DeStefano2

  • 1Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.

Current Cancer Drug Targets
|April 25, 2020
PubMed
Summary
This summary is machine-generated.

Genomic insights have transformed acute myeloid leukemia (AML) understanding and led to new FDA-approved drugs. However, challenges like toxicity and resistance persist, requiring further therapeutic advancements for better patient outcomes.

Keywords:
Acute myeloid leukemia (AML)clinical implicationsdrug transportersgenomic landscapehematologic malignancytherapeutics

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K

Related Experiment Videos

Last Updated: Dec 23, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K

Area of Science:

  • Hematology
  • Oncology
  • Genomics

Background:

  • Genomic and molecular understanding of acute myeloid leukemia (AML) has significantly evolved.
  • This progress has refined prognostication for patients undergoing standard chemotherapy.
  • Increased knowledge has contributed to new Food and Drug Administration (FDA) drug approvals for AML.

Purpose of the Study:

  • To review the impact of genomics on clinical care for AML patients.
  • To highlight newly approved FDA drugs for AML treatment.
  • To discuss challenges and opportunities in AML therapy.

Main Methods:

  • Literature review of genomic and molecular studies in AML.
  • Analysis of FDA drug approvals related to AML.
  • Discussion of current therapeutic challenges and future directions.

Main Results:

  • Genomic advancements have improved AML prognostication and treatment strategies.
  • Eight new FDA-approved drugs represent significant progress in AML therapy.
  • Despite advances, patient outcomes for AML remain challenging.

Conclusions:

  • Genomics has revolutionized AML understanding and treatment, leading to new drug approvals.
  • Key challenges in AML treatment include off-target toxicity, drug transporters, clonal heterogeneity, and adaptive resistance.
  • Further research into overcoming these challenges is crucial for improving AML patient outcomes.